CS Connected Graphic 1170X292px 10

News

Rockley Signs Supply Agreement for Wrist-Worn Biomarker Tech

10th August 2022

OXFORD, England, Aug. 10, 2022 — Rockley Photonics has signed a supply agreement — outlining the customer’s initial purchase commitment for 2023 — and received the first commercial purchase order for its noninvasive biomarker sensing wristbands. Rockley identified the unnamed customer for the commercial purchase as a “global health care technology provider.” 

Rockley’s Bioptx Baseline devices included in the order will feature Rockley’s biosensing technology. The complete end-to-end solution enables the noninvasive, continuous, and near-real-time monitoring of multiple biomarkers.

The form and function of the wearable device allow it to be worn on the wrist or elsewhere on the body, depending on the use case and physical requirements. The Bioptx band features a flexible hardware design that will support a range of software stacks that can be customized to address specific needs of various customers. The software can be adjusted to optimize battery life for extended use or maximize performance for intensive duty cycles.
Rockley’s Bioptx Baseline devices included in its cursory order will use Rockley’s biosensing technology to enable the noninvasive, continuous, and near-real-time monitoring of multiple biomarkers. The initial units of the solution are expected to ship in the fourth quarter of this year. Courtesy of Business Wire via Rockley Photonics.


Rockley’s Bioptx Baseline devices included in its cursory order will use Rockley’s biosensing technology to enable the noninvasive, continuous, and near-real-time monitoring of multiple biomarkers. The initial units of the solution are expected to ship in the fourth quarter of this year. Courtesy of Business Wire via Rockley Photonics. 


The offering is supported by Rockley's photonics-based biomarker sensing platform that miniaturizes the capabilities of lab-based spectrometers onto a single wrist-worn device. Rockley said it expects to work with its partners and customers toward receiving clearance of Rockley-powered wearable devices from the U.S. Food and Drug Administration and other regulatory agencies.

“This is a pivotal moment for Rockley as our medtech customers begin to deploy wearable, noninvasive biosensing solutions that could help improve patient treatment,” said Andrew Rickman, chairman and CEO of Rockley.

Rickman said Rockley plans high-volume production for 2023. According to a company press release, Rockley expects initial units of the Bioptx Baseline devices to ship in the fourth quarter of 2022, which could put the technology on the wrists of end users by the end of this year.

*This article has been updated for accuracy to further distinguish between the Rockley's commercial order and signed supply agreement.


Other news

Industry-Partners

KLA Announces Plans to Build a New R&D and Manufacturing Facility in Newport, Wales

30 September 2022
KLA Announces Plans to Build a New R&D and Manufacturing Facility in Newport, Wales

CSconnected

New IOP report "Physics: Investing in our Future"

21 September 2022
New IOP report "Physics: Investing in our Future"

Industry-Partners

IQE: H1 2022 Results

06 September 2022